http://www.arizonabiotech.com/
http://groups.yahoo.com/group/biotech-news/
http://www.arizonaentrepreneurs.com/
http://www.azhttp.com/
| My Groups | biotech-news Main Page | |
Rosetta Biosoftware Announces the Rosetta Syllego System for Genetic
Data Management and Analysis
New Product to be Showcased at Workshop at
11 th Annual Human Genome Meeting in Helsinki , Finland
SEATTLE, Wash., May 19, 2006 Rosetta Biosoftware announced today
the availability of their new product, the Rosetta Syllego Genetic
Data Management and Analysis System for genetic studies. The system
is designed to effectively manage genetic data from disparate
sources and combine relevant genotypic and phenotypic study data so
that scientists can spend their time analyzing data and drawing
conclusions instead of contending with data from multiple sources.
"Customers and prospects have shared with us their frustrations for
finding a resource that can capture and store data from a range of
sources, so we designed the Syllego system to address this need. The
system enables researchers to plan and conduct genetic studies using
various commercial genotyping platforms and vendor assays and
integrate relevant study data," said Yelena Shevelenko, vice
president and general manager of Rosetta Biosoftware. "Further, the
system includes quality control tools to prevent loss of time in
downstream analyses as well as automation and project management
tools to record and plan analysis workflows and catalog data for
future studies. All of these tools help scientists spend less time
transforming and formatting data and more time analyzing data."
The Syllego system also includes basic data analysis tools and the
ability to integrate study data with common statistical packages,
such as R. The system will be demonstrated at the Human Genome
Organisation conference in Helsinki, Finland, May 31 - June 3, as
well at Rosetta Biosoftware's upcoming conference, the Rosetta
Technology Forum, also in Helsinki, June 4 - 5. To register for this
forum free of charge, please visit www.rosettabio.com/conferences.
About the Rosetta Syllego System
The Rosetta Syllego system is Rosetta Biosoftware's practical
solution for genetic data management and analysis. Designed for
scientists engaged in genetic studies, such as eQTL or genome-wide
association or linkage, the system is a resource for managing
genetic variation information. The system captures and stores SNP
genotyping assay data and information from leading technology
platforms so that you can better plan and execute genetic studies.
QC tools help you verify that data are high-quality to prevent loss
of time in downstream analyses. Application tools enable you to
combine relevant genotypic and phenotypic study data to interface
with the statistical environment of your choice. And automation
tools enable you to analyze and catalog study data and analysis
results, so that you can incorporate findings into future studies.
Because the system is built upon Rosetta Biosoftware's existing
informatics platform, it can integrate with other Rosetta
Biosoftware products, your own in-house tools, or other third-party
platforms. For more information on the Syllego system, please visit
www.rosettabio.com/syllego.
About Rosetta Biosoftware
Rosetta Biosoftware is a leading provider of informatics solutions
for life science research. Its comprehensive software solutions,
including the Rosetta Resolver, Rosetta Elucidator, and Rosetta
Syllego systems, empower life scientists with advanced, scalable,
and easy-to-use analysis platforms that accelerate discovery
research. Rosetta Biosoftware is a business unit of Rosetta
Inpharmatics LLC, a wholly owned subsidiary of Merck & Co., Inc.
(NYSE: MRK). More information about Rosetta Biosoftware is available
at www.rosettabio.com.
Forward-Looking Statements
This press release contains "forward-looking statements" as that
term is defined in the Private Securities Litigation Reform Act of
1995. These statements involve risks and uncertainties, which may
cause results to differ materially from those set forth in the
statements. The forward-looking statements may include statements
regarding product development, product potential, or financial
performance. No forward-looking statement can be guaranteed, and
actual results may differ materially from those projected. Neither
Rosetta Inpharmatics nor Merck & Co., Inc. undertakes any obligation
to publicly update any forward-looking statement, whether as a
result of new information, future events, or otherwise. Forward-
looking statements in this press release should be evaluated
together with the many uncertainties that affect the business of
Merck & Co., Inc. including, among others, the extent to which
Rosetta Inpharmatics' technology platform can be used in drug
discovery programs, uncertainty of market acceptance of Rosetta
Inpharmatics' technologies, ability to compete against existing
technologies, and those mentioned in the cautionary statements in
Item 1 of Merck's Form 10-K for the year ended Dec. 31, 2005, and in
its periodic reports on Form 10-Q and Form 8-K (if any) which are
incorporated by reference.
Rosetta Resolver and Rosetta Elucidator are U.S. registered
trademarks of Rosetta Inpharmatics LLC. Rosetta Syllego is a
trademark of Rosetta Inpharmatics LLC.
YAHOO! GROUPS LINKS
[EMAIL PROTECTED]
